-
On Roxastat in the vortex of controversy
Time of Update: 2021-09-04
Roxastat has also become the first innovative drug to be marketed in the world for the first time in China, which has aroused global attention; on August 16, 2019, Roxastat was approved to treat non-dialysis patients with renal anemia through the priority review process .
-
North China Pharmaceuticals has a lower limit!
Time of Update: 2021-09-04
It was once the cradle of the pharmaceutical industry in New China and was known as the “eldest son of medicine” of the Republic. North China Pharmaceuticals, one of the four major pharmaceutical fac
-
4 Chinese medicines including Shenqi Wuweizi Capsules were converted into over-the-counter medicines
Time of Update: 2021-09-04
Shenqi Schisandra capsules manual Precautions include cold and fever patients should not be taking high blood pressure in patients with heart disease, liver disease, diabetes, kidney disease should be taken under the guidance of doctors, pregnant women, lactating women should be taken under the guidance of doctors and so on .
-
Fosun Pharma Announces 2021 Interim Results, Innovation Results Continue to Land, International Operation Capability Further Improved
Time of Update: 2021-09-04
73%;· The joint venture Fosun Kate’s Yi Kai Da is the first CAR-T cell therapy product approved for marketing in China;· Fubitai® (mRNA Covid-19 vaccine, BNT162b2) was included in the government vaccination program in Hong Kong and Macau in the first half of the year; and it plans to supply 15 million doses of mRNA Covid-19 vaccine to Taiwan, China .
-
How does the differentiation of the five new-generation BTK inhibitors that have been approved globally reflect?
Time of Update: 2021-09-04
In addition to improving the specificity of covalent irreversible BTK inhibitors, the development of new reversible BTK inhibitors to overcome drug resistance, a new generation of products that can cross the blood-brain barrier, BTK targeted protein degradation agents, etc.
-
Patent original research drugs account for only 9% of the cost. How does China build a multi-level medical security system?
Time of Update: 2021-09-04
European and American countries have a relatively clear granularity of legislation, and a series of legal regulations are imposed on the population, scope, encouragement and restriction policies of social insurance and commercial health insurance .
-
A batch of drug discontinuation recalls involve multiple preparations such as Shuanghuanglian and Omeprazole
Time of Update: 2021-09-04
A few days ago, the Sichuan Provincial Food and Drug Administration issued a notice stating that the three batches of drugs produced by three drug manufacturers including Shanxi Jinhuahuixing Pharmaceutical Co.
-
Quotations of 34 large-species collection pharmaceutical companies started
Time of Update: 2021-09-04
According to the centralized procurement rules, the company's quotation shall not be higher than the current minimum bid-winning price of the company in the two provinces of Gansu and Shaanxi .
-
CDE Yang Zhimin, Xie Songmei: Drug review promotes the development of pediatric drugs through multiple channels, and product reviews are gradually increasing!
Time of Update: 2021-09-04
She said: “Through early communication in clinical research and development, we recommend that the original research company conduct clinical trials in China as soon as possible to provide data support for scientific decision-making in drug review .
-
PD-1 antibody "partner" TIL therapy challenges advanced lung cancer
Time of Update: 2021-09-04
Researchers at the Moffitt Cancer Center in the United States initiated an evaluation of the PD-1 antibody nivolumab (trade name: Odivo) in combination with tumor infiltrating lymphocytes (TIL) for the treatment of advanced non-small cell lung cancer (NSCLS) Phase I clinical trial .
-
CDE Director Kong Fanpu: Innovative drug review set a new record, and the international drug review track accelerated
Time of Update: 2021-09-04
With the year-on-year increase in the number of drug registration application tasks and the high technical content of the declared varieties, the overall completion rate of the innovative drug-related tasks of the Center for Drug Evaluation exceeded 90% within the time limit .
-
National centralized procurement of high-value consumables for artificial joints will be fully launched on September 14
Time of Update: 2021-09-04
Price limit rules for four types of products: Various reporting requirements Eligibility for declaration: Reporting companies to have achieved this focus with the amount of purchased product legally qualified medical device registrant ( proxy person), reporting companies must clearly serves regional, and promised each product system corresponds to all models for the procurement to meet the regional purchasing demand cycle .
-
How can pharmaceutical companies gain market access to proprietary Chinese medicines and biological preparations?
Time of Update: 2021-09-04
If the initial reporting volume of new entrants of biosimilar drugs is very low, when medical institutions go to reverse the selection of manufacturers, the new entrants are even less likely to be reversed, and the incentives for new entrants to reduce prices are insufficient .
-
A group of pharmaceutical companies attacked 6 billion large varieties: CSPC, Kelun, Yangtze River...
Time of Update: 2021-09-04
Cyberlan found from the official website of the State Food and Drug Administration that in addition to the specifications of oseltamivir phosphate capsules of 75mg, Dongyang Pharmaceutical has also been approved for 30mg and 45mg recently.
-
781 drugs withdrew from the procurement platform: either production was suspended or costs increased...
Time of Update: 2021-09-04
As for the reasons for withdrawing from the provincial procurement platform, it mainly involves many aspects, including rising costs and inability to supply at current prices; suspension of production; adjustment of production lines; price inversion; raw material problems and inability to produce.
-
News analysis: Where did you go to find the new crown drug?
Time of Update: 2021-09-04
"Speed type" contestant-biological macromolecular drugs At present, the rapid progress in global research and development is biomacromolecule drugs, mainly antibodies, including single-drug monoclonal antibodies and combined use of "antibody cocktail therapy" .
-
Johnson & Johnson/Theravance ulcerative colitis drug idencitinib failed Phase II clinical trial
Time of Update: 2021-09-04
A few days ago, because the drug's Phase 2 dose exploration study in ulcerative colitis failed to reach the primary endpoint, the outside world has doubts about the prospects of this JAK inhibitor in indications including ulcerative colitis .
-
There is not much time left for insulin!
Time of Update: 2021-09-04
In the end, this special procurement with a total purchase volume of 1,705,700 units led to a 43% reduction in the unit price of some successful insulin drugs .
-
The new crown DNA vaccine is approved to deal with the Delta strain and can be used to vaccinate adolescents
Time of Update: 2021-09-04
Prior to the approval of ZyCov-D, the fastest progress in clinical research was the new crown DNA vaccine pGX9501/INO-4800 jointly developed by China Aiweixin (Suzhou) Biopharmaceuticals and Inovio Pharmaceuticals of the United States, as well as those developed by Anges Inc.
-
Huiyu's first new drug is coming to grab 6 billion cardiovascular varieties
Time of Update: 2021-09-04
0 Chinese Drug Evaluation Database At present, in addition to Huiyu’s clinical application of new drugs, Livzon has already submitted an application for the generic listing of 4 types of butylphthalide sodium chloride injection and has been approved for clinical use.
